Hostname: page-component-8448b6f56d-c4f8m Total loading time: 0 Render date: 2024-04-23T09:46:17.106Z Has data issue: false hasContentIssue false
  • English
  • Français

Transdermal Selegiline: The New Generation of Monoamine Oxidase Inhibitors

Published online by Cambridge University Press:  07 November 2014

Ashwin A. Patkar ,
Chi-Un Pae  and
Prakash S. Masand
Get access Rights & Permissions [Opens in a new window]

Abstract

The clinical use of monoamine oxidase inhibitors (MAOIs) has declined due to concerns about food and drug interactions and waning physician experience. Evidence indicates that MAOIs are effective in depressive disorders, in particular depression with atypical features. Efforts to address safety issues have led to the development of more selective and reversible MAOIs, such as moclobemide. Selegiline, a selective monoamine oxidase B inhibitor, has been approved for the adjunctive treatment of Parkinson's disease at low doses. At higher doses, oral selegiline is also effective in major depressive disorder (MDD) but loses its selectivity and has the potential for tyramine interactions.To overcome these problems, a transdermal formulation of selegiline, the selegiline transdermal system (STS), was developed with novel pharmacokinetic and pharmacodynamic properties. Compared with oral administration, transdermal selegiline leads to sustained plasma concentrations of the parent compound, increasing the amount of drug delivered to the brain and decreasing metabolite production. In addition, STS allows targeted inhibition of central nervous system monoamine A (MAO-A) and monoamine B isoenzymes with minimal effects on MAO-A in the gastrointestinal and hepatic systems, thereby reducing the risk of interactions with tyramine-rich foods (the “cheese-reaction”). Clinical trials have found 6 mg/24 hours of STS to be effective in MDD without the need for dietary restrictions. The efficacy and safety profile of STS supports its use in MDD. It is possible that STS may demonstrate benefit in MDD with atypical features or MDD resistant to other antidepressants. However, more research is needed. Clinicians should familiarize themselves with the properties and indications for the new generation of MAOIs.

Type
Review Articles
Information
CNS Spectrums , Volume 11 , Issue 5 , May 2006 , pp. 363 - 375
Copyright
Copyright © Cambridge University Press 2006

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

1.Robinson, DS. Monoamine oxidase inhibitors: a new generation. Psychopharmacol Bull. 2002;36:124–138.Google Scholar
2.Ban, TA. Pharmcotherapy of depression: a historical analysis. J Neural Transm. 2001;108:707–716.CrossRefGoogle Scholar
3.Amsterdam, JD, Chopra, M. Monoamine oxidase inhibitors revisited. Psychiatr Ann. 2001;31:361–370.Google Scholar
4.Asatoor, AM, Levi, AJ, Milne, MD. Tranylcypromine and cheese. Lancet. 1963;54:733–734.CrossRefGoogle Scholar
5.Horwitz, D, Lovenberg, W, Engelman, K, Sjoerdsma, A. Monoamine oxidase inhibitors, tyramine, and cheese. JAMA. 1964;188:1108–1110.Google Scholar
6.Johnson, AG. Monoamine oxidase inhibitors. Br Med J. 1968;2:433.CrossRefGoogle ScholarPubMed
7.Billett, EE. Monoamine oxidase (MAO) in human peripheral tissues. Neurotoxicology. 2004;25:139–148.Google Scholar
8.Yamada, M, Yasuhara, H. Clinical pharmacology of MAO inhibitors: safety and future. Neurotoxicology. 2004;25:215–221.Google Scholar
9.Riederer, P, Konradi, C, Schay, V, et al.Localization of MAO-A and MAO-B in human brain: a step in understanding the therapeutic action of L-deprenyl. Adv Neurol. 1987;45:111–118.Google Scholar
10.Mawhinney, M, Cole, D, Azzaro, AJ. Daily transdermal administration of selegiline to guinea-pigs preferentially inhibits monoamine oxidase activity in brain when compared with intestinal and hepatic tissues. J Pharm Pharmacol. 2003;55:27–34.Google Scholar
11.Lotufo-Neto, F, Trivedi, M, Thase, ME. Meta-analysis of the reversible inhibitors of monoamine oxidase type A moclobemide and brofaromine for the treatment of depression. Neuropsychopharmacology. 1999;20:226–247.Google Scholar
12.Johnston, JP. Some observations upon a new inhibitor or monoamine oxidase in brain tissue. Biochem Pharmacol. 1968;17:1285–1297.CrossRefGoogle ScholarPubMed
13.Lipper, S, Murphy, DL, Slater, S, Buchsbaum, MS. Comparative behavioral effects of clorgyline and pargyline in man: a preliminary evaluation. Psychopharmacology (Berl). 1979;62:123–128.Google Scholar
14.Chen, DT, Ruch, R. Safety of moclobemide in clinical use. Clin Neuropharmacol. 1993;16(suppl 2):S63–S68.Google ScholarPubMed
15.Youdim, MB. The advent of selective monoamine oxidase A inhibitor antidepressants devoid of the cheese reaction. Acta Psychiatr Scand Suppl. 1995;386:5–7.Google Scholar
16.Thase, ME, Frank, E, Mallinger, AG, Hamer, T, Kupfer, DJ. Treatment of imipramine-resistant recurrent depression, III: Efficacy of monoamine oxidase inhibitors. J Clin Psychiatry. 1992;53:5–11.Google ScholarPubMed
17.Lonnqvist, J, Sintonen, H, Syvalahti, E, et al.Antidepressant efficacy and quality of life in depression: a double-blind study with moclobemide and fluoxetine. Acta Psychiatr Scand. 1994;89:363–369.Google Scholar
18.Riederer, P, Youdim, MB. Monoamine oxidase activity and monoamine metabolism in braines of parkinsonian patients treated with I-deprenyl. J Neurochem. 1986;46:1359–1365.Google Scholar
19.Glover, V, Elsworth, JD, Sandler, M. Dopamine oxidation and its inhibition by I-deprenyl in man. J Neural Transm Suppl. 1980;16:163–172.Google Scholar
20.Birkmayer, W. Deprenyl (selegiline) in the treatment of Parkinson's disease. Acta Neurol Scand Suppl. 1983;95:103–105.Google Scholar
21.Tetrud, JW, Langston, JW. The effect of deprenyl (selegiline) on the natural history of Parkinson's disease. Science. 1989;245:519–522.Google Scholar
22.Barrett, JS, Hochadel, TJ, Morales, RJ, et al.Pharmacokinetics and safety of a selegiline transdermal system relative to single-dose oral administration in the elderly. Am J Ther. 1996;3:688–698.CrossRefGoogle ScholarPubMed
23.Rohatagi, S, Barrett, JS, DeWitt, KE, Morales, RJ. Integrated pharmacokinetic and metabolic modeling of selegiline and metabolites after transdermal administration. Biopharm Drug Dispos. 1997;18:567–584.Google Scholar
24.Wecker, L, James, S, Copeland, N, Pacheco, MA. Transdermal selegiline: targeted effects on monoamine oxidases in the brain. Biol Psychiatry. 2003;54:1099–1104.Google Scholar
25.Mann, JJ, Aarons, SF, Wilner, PJ, et al.A controlled study of the antidepressant efficacy and side effects of L-deprenyl. Arch Gen Psychiatry. 1989;46:45–50.Google Scholar
26.McGrath, PJ, Stewart, JW, Harrison, W, Wager, S, Nunes, EW, Quitkin, FM. A placebo-controlled trial of L-deprenyl in atypical depression. Psychopharmacol Bull. 1989;25:63–67.Google Scholar
27.Sunderland, T, Cohen, RM, Molchan, S, et al.High-dose selegiline in treatment-resistant older depressive patients. Arch Gen Psychiatry. 1994;51:607–615.CrossRefGoogle ScholarPubMed
28.Trivedi, MH, Rush, AJ, Wisniewski, SR, et al.Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry. 2006;163:28–40.CrossRefGoogle ScholarPubMed
29.Clarke, A, Brewer, F, Johnson, ES, et al.A new formulation of selegiline: improved bioavailability and selectivity for MAO-B inhibition. J Neural Transm. 2003;110:1241–1255.Google Scholar
30.Seager, H. Drug-delivery products and the Zydis fast-dissolving dosage form. J Pharm Pharmacol. 1998;50:375–382.Google Scholar
31.Tetrud, JW, Koller, WC. A novel formulation of selegiline for the treatment of Parkinson's disease. Neurology. 2004;63(7 suppl 2):S2–S6.CrossRefGoogle ScholarPubMed
32.Finberg, JP, Lamensdorf, I, Weinstock, M, Schwartz, M, Youdim, MB. Pharmacology of rasagiline (N-propargyl-1R-aminoindan). Adv Neurol. 1999;80:495–499.Google ScholarPubMed
33.Parkinson Study Group. A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. Arch Neurol. 2002;59:1937–1943.Google Scholar
34.Anderson, MC, Hasan, F, McCrodden, JM, Tipton, KF. Monoamine oxidase inhibitors and the cheese effect. Neurochem Res. 1993;18:1145–9.Google Scholar
35.Finberg, JP, Tenne, M, Youdim, MB. Tyramine antagonistic properties of AGN 1135, an irreversible inhibitor of monoamine oxidase type B. Br J Pharmacol. 1981;73:65–74.Google Scholar
36.Youdim, MB, Riederer, PF. A review of the mechanisms and role of monoamine oxidase inhibitors in Parkinson's disease. Neurology. 2004;63(7 suppl 2):S32–35.CrossRefGoogle ScholarPubMed
37.Da Prada, M, Zurcher, G, Wuthrich, I, Haefely, WE. On tyramine, food, beverages and the reversible MAO inhibitor moclobemide. J Neural Transm Suppl. 1988;26:31–56.Google ScholarPubMed
38.McCabe, BJ. Dietary tyramine and other pressor amines in MAOI regimens: a review. J Am Diet Assoc. 1986;86:1059–1064.Google Scholar
39.Wilkosz, MF. Transdermal Drug Delivery. Part 1: Current Status. US Pharmacist [serial online/. 2003;28. Available at: http://www.uspharmacist.com/index.asp?show=article&page=8_1061.htm. Accessed November 30, 2005.Google Scholar
40.Oh, C, Murray, B, Bhattacharya, N, Holland, D, Tatton, WG. L-deprenyl alters the survival of adult murine facial motoneurons after axotomy: increases in vulnerable C57BL strain but decreases in motor neuron degeneration mutants. J Neurosci Res. 1994;38:64–74.Google Scholar
41.Rohatagi, S, Barrett, JS, McDonald, LJ, Morris, EM, Darnow, J, DiSanto, AR. Selegiline percutaneous absorption in various species and metabolism by human skin. Pharm Res. 1997;14:50–55.Google Scholar
42. EMSAM® selegiline transdermal system new drug application 21,336/21,708. Food and Drug Administriation Web site. Available at: http://www.fda.gov/ohrms/dockets/ac/05/briefing/2005-4186B2_01_01_Somerset-EMSAM.pdf. Accessed October 26, 2005.Google Scholar
43.Krishnan, R. Advances in psychopharmacology: MAOIs. Scientific report session. Abstract presented at: the 157th Annual Meeting of the American Psychiatric Association: May 1-6, 2004: New York, NY.Google Scholar
44.Wagner, GC, Walsh, SL. Evaluation of the effects of inhibition of monoamine oxidase and senescence on methamphetamine-induced neuronal damage. Int J Dev Neurosci. 1991;9:171–174.CrossRefGoogle ScholarPubMed
45.Cadet, JL, Sheng, P, Ali, S, Rothman, R, Carlson, E, Epstein, C. Attenuation of methamphetamine-induced neurotoxicity in copper/zinc superoxide dismutase transgenic mice. J Neurochem. 1994;62:380–383.Google Scholar
46.Gordon, MN, Muller, CD, Sherman, KA, Morgan, DG, Azzaro, AJ, Wecker, L. Oral versus transdermal selegiline: antidepressant-like activity in rats. Pharmacol Biochem Behav. 1999;63:501–506.Google Scholar
47.EMSAM [package insert]. Princeton, NJ: Bristol-Myers Squibb Company: 2006.Google Scholar
48.Barrett, JS, Hochadel, TJ, Morales, RJ, et al.Pressor response to tyramine after single 24-hour application of a selegiline transdermal system in healthy males. J Clin Pharmacol. 1997;37:238–247.Google Scholar
49.Berlin, I, Zimmer, R, Cournot, A, Payan, C, Pedarriosse, AM, Puech, AJ. Determination and comparison of the pressor effect of tyramine during long-term moclobemide and tranylcypromine treatment in healthy volunteers. Clin Pharmacol Ther. 1989;46:344–351.Google Scholar
50.Simpson, GM, Gratz, SS. Comparison of the pressor effect of tyramine after treatment with phenelzine and moclobemide in healthy male volunteers. Clin Pharmacol Ther. 1992;52:286–291.CrossRefGoogle ScholarPubMed
51.VanDenBerg, CM, Blob, LF, Gerrick, G, et al. Blood pressure response produced by a tyramine-enriched meal following multiple does administration of 20cm2/20mg selegiline transdermal system (STS) in health male volunteers. Abstract presented at: Annual Meeting of the New Clinical Drug Evaluation Unit. May 30-June 2, 2000: Boca Raton, FL.Google Scholar
52.Mccabe, BJ, Gurley, BJ. Transdermal selegiline and dietary tyramine: is there a concern? J Am Diet Assoc. 2003:103(9 suppl 1):A25.Google Scholar
53.Shulman, KI, Walker, SE. A Reevaluation of Dietary Restrictions for Irreversible Monoamine Oxidase Inhibitors. Psychiatr Ann. 2001;31:378–384.Google Scholar
54.Azzaro, AJ, Blob, LF, Kemper, EM, Sharoky, M, VanDenBerg, CM. Pressor effects of oral tyramine and over-the-counter (OTC) sympathomimetic amines following steady-state transdermal administration of selegiline to healthy volunteers. In: Scientific Abstracts of the 2000 Annual Meeting of the American College of Neuropsychopharmacology. Nashville, Tenn: Abstract 268.Google Scholar
55.Blob, LF, VanDenBerg, CM, Kemper, EM, et al. Safety of selegiline transdermal system: concomitant administration of pseudoephedrine, a sympathomimetic amine. Abstract presented at: Annual Meeting of the New Clinical Drug Evaluation Unit. May 28-31, 2001: Phoenix, Ariz.Google Scholar
56.Sternbach, H. The serotonin syndrome. Am J Psychiatry. 1991;148:705–13.Google Scholar
57.Hilton, SE, Maradit, H, Moller, HJ. Serotonin syndrome and drug combinations: focus on MAOI and RIMA. Eur Arch Psychiatry Clin Neurosci. 1997;247:113–119.Google Scholar
58.Richard, IH, Kurlan, R, Tanner, C, et al.Serotonin syndrome and the combined use of deprenyl and an antidepressant in Parkinson's disease. Parkinson Study Group. Neurology. 1997;48:1070–1077.Google Scholar
59.Bodkin, JA, Amsterdam, JD. Transdermal selegiline in major depression: a double-blind, placebo-controlled, parallel-group study in outpatients. Am J Psychiatry. 2002;159:1869–1875.Google Scholar
60.Amsterdam, JD. A double-blind, placebo-controlled trial of the safety and efficacy of selegiline transdermal system without dietary restrictions in patients with major depressive disorder. J Clin Psychiatry. 2003;64:208–214.CrossRefGoogle ScholarPubMed
61.Guelfi, JD, Strub, N, Loft, H. Efficacy of intravenous citalopram compared with oral citalopram for severe depression. Safety and efficacy data from a double-blind, double-dummy trial. J Affect Disord. 2000;58:201–209.Google Scholar
62.Moonsammy, G, Blob, LF, Sharoky, M, VanDenBerg, CM, Azzaro, AJ. Safety of selegiline transdermal system in long-term prevention of relapse of depression. Abstract presented at: the Annual Meeting of the New Clinical Drug Evaluation Unit: May 27-30, 2003: Boca Raton, FL.Google Scholar
63.Pauporte, M, Azzaro, AJ, Moonsammy, G, Maibach, H. Selegiline Transdermal System (STS): Assessment of dermal safety in human. J Toxicol. 2004;23:179–187.Google Scholar
64.Robinson, DS, Campbell, IC, Walker, M, Statham, NJ, Lovenberg, W, Murphy, DL. Effects of chronic monoamine oxidase inhibitor treatment on biogenic amine metabolism in rat brain. Neuropharmacology. 1979;18:771–776.CrossRefGoogle ScholarPubMed
65.Campbell, IC, Shiling, DJ, Lipper, S, Slater, S, Murphy, DL. A biochemical measure of mono-amine oxidase type A and B inhibitor effects in man. J Psychiatr Res. 1979;15:77–84.Google Scholar
66.Blier, P, De Montigny, C, Azzaro, AJ. Modification of serotonergic and noradrenergic neurotransmissions by repeated administration of monoamine oxidase inhibitors: electrophysiological studies in the rat central nervous system. J Pharmacol Exp Ther. 1986;237:987–994.Google Scholar
67.Stamford, JA, Davidson, C, McLaughlin, DP, Hopwood, SE. Control of dorsal raphe 5-HT function by multiple 5-HT(1) autoreceptors: parallel purposes or pointless plurality? Trends Neurosci. 2000;23:459–465.Google Scholar
68.Cesura, AM, Pletscher, A. The new generation of monoamine oxidase inhibitors. Prog Drug Res. 1992;38:171–297.Google Scholar
69.Magyar, K, Palfi, M, Tabi, T, Kalasz, H, Szende, B, Szoko, E. Pharmacological aspects of L-deprenyl. Curr Med Chem. 2004;11:2017–2031.Google Scholar
70.Khanzode, SD, Dakhale, GN, Khanzode, SS, Saoji, A, Palasodkar, R. Oxidative damage and major depression: the potential antioxidant action of selective serotonin re-uptake inhibitors. Redox Rep. 2003;8:365–370.Google Scholar
71.Nierenberg, AA, Alpert, JE, Pava, J, Rosenbaum, JF, Fava, M. Course and treatment of atypical depression. J Clin Psychiatry. 1998;59(suppl 18):5–9.Google Scholar
72.Asnis, GM, McGinn, LK, Sanderson, WC. Atypical depression: clinical aspects and noradrenergic function. Am J Psychiatry. 1995;152:31–36.Google ScholarPubMed
73.Angst, J, Gamma, A, Sellaro, R, Zhang, H, Merikangas, K. Toward validation of atypical depression in the community: results of the Zurich cohort study. J Affect Disord. 2002;72:125–138.Google Scholar
74.Henkel, V, Mergl, R, Allgaier, AK, Kohnen, R, Moller, HJ, Hegerl, U. Treatment of depression with atypical features: a meta-analytic approach. Psychiatry Res. 2006;141:89–101.Google Scholar
75.McGrath, PJ, Stewart, JW, Janal, MN, Petkova, E, Quitkin, FM, Klein, DF. A placebo-controlled study of fluoxetine versus imipramine in the acute treatment of atypical depression. Am J Psychiatry. 2000;157:344–350.Google Scholar
76.Nolen, WA, van de Putte, JJ, Dijken, WA, et al.Treatment strategy in depression. II. MAO inhibitors in depression resistant to cyclic antidepressants: two controlled crossover studies with tranylcypromine versus L-5-hydroxytryptophan and nomifensine. Acta Psychiatr Scand. 1983;78:676–683.Google Scholar
77.Anderson, IM, Nutt, DJ, Deakin, JF. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 1993 British Association for Psychopharmacology guidelines. British Association for Psychopharmacology. J Psychopharmacol. 2000;14:3–20.Google Scholar
78.Amsterdam, JD, Shults, J. MAOI efficacy and safety in advanced stage treatment-resistant depression–a retrospective study. J Affect Disord. 2005;89:183–188.CrossRefGoogle ScholarPubMed
79.McGrath, PJ, Stewart, JW, Nunes, EV, et al.A double-blind crossover trial of imipramine and phenelzine for outpatients with treatment-refractory depression. Am J Psychiatry 1993;150:118–123.Google ScholarPubMed
80.Mohammadi, MR, Ghanizadeh, A, Alaghband-Rad, J, Tehranidoost, M, Mesgarpour, B, Soori, H. Selegiline in comparison with methylphenidate in attention deficit hyperactivity disorder children and adolescents in a double-blind, randomized dinicaf trial. J Child Adoles Psychopharmacol. 2004;14:418–425.Google Scholar
81.Mechcatie, E. Transdermal MAO inhibitor patch effective for ADHD. Clinical Psychiatry News. June 2003:18.Google Scholar
82.Houtsmuller, EJ, Notes, LD, Newton, T, et al.Transdermal selegiline and intravenous cocaine: safety and interactions. Psychopharmacology (Berl). 2004;172:31–40.Google Scholar
83.Bartzokis, G, Beckson, M, Newton, T, et al.Selegiline effects on cocaine-induced changes in medial temporal lobe metabolism and subjective ratings of euphoria. Neuropsychopharmacology 1999;20:582–590.Google Scholar
84.Biberman, R, Neumann, R, Katzir, I, Gerber, Y. A randomized controlled trial of oral selegiline plus nicotine skin patch compared with placebo plus nicotine skin patch for smoking cessation. Addiction. 2003;98:1403–1407.Google Scholar
85.George, TP, Vessicchio, JC, Termine, A, Jatlow, PI, Kosten, TR, O'Malley, SS. A preliminary placebo-controlled trial of selegiline hydrochloride for smoking cessation. Biol Psychiatry. 2003;53:136–143.Google Scholar
86.Bodkin, JA, Cohen, BM, Salomon, MS, Cannon, SE, Zornberg, GL, Cole, JO. Treatment of negative symptoms in schizophrenia and schizoaffective disorder by selegiline augmentation of antipsychotic medication. A pilot study examining the role of dopamine. J Nerv Ment Dis. 1996;184:295–301.Google Scholar
87.Gupta, S, Droney, T, Kyser, A, Keller, P. Selegiline augmentation of antipsychotics for the treatment of negative symptoms in schizophrenia. Compr Psychiatry. 1999;40:148–150.Google Scholar
88.Fiedorowicz, JG, Swartz, KL. The role of monoamine oxidase inhibitors in current pychiatric practice. J Psychiatr Pract. 2004;10:239–248.Google Scholar